Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.55 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977661 | 0.89 | CDC7 (0.70) | CDC7DBF4HDAC6PTGDR2MAPT | |
| SCHEMBL12922065 | 0.87 | CDC7 (0.57) | PTGS2CDC7DBF4HDAC6PTGDR2 | |
| SCHEMBL976360 | 0.87 | PTGS2 (0.58) | PTGS2PTGDR2APPMAPTTRPM8 | |
| SCHEMBL13845097 | 0.85 | PTGS2 (0.53) | PTGS2HDAC6PTGDR2APPMAPT | |
| SCHEMBL10506565 | 0.78 | PTGS2 (0.78) | PTGS2PTGDR2APPMAPT | |
| SCHEMBL12922064 | 0.77 | TRPM8 (0.53) | PTGS2CDC7DBF4PTGDR2APP | |
| SCHEMBL975727 | 0.77 | CDC7 (0.86) | CDC7DBF4HDAC6PTGDR2MAPT | |
| SCHEMBL14148658 | 0.75 | LMNA (0.76) | CDC7DBF4PTGDR2MAPTPOLB | |
| SCHEMBL16038025 | 0.72 | ALDH1A1 (0.60) | CDC7DBF4PTGDR2MAPTPOLB | |
| SCHEMBL7833473 | 0.72 | PTGS2 (1.00) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| EP-2217588-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009055917-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | PTGS2 3634/4885CDC7 2481/4885DBF4 1443/4885 |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | PTGS2 3634/4885CDC7 2481/4885DBF4 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.